Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways
Journal Title: Global Journal of Cancer Therapy - Year 2016, Vol 2, Issue 1
Abstract
Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR) α, KIT, and RET. The VEGFR and FGFR signaling pathways are the master regulators of normal and tumor angiogenesis. Lenvatinib showed significant activity in patients with radioiodine-refractory thyroid cancer in a Phase III study and is used in the United States, the European Union, and Japan. Moreover, based on Phase II study, lenvatinib has been approved in the United States for the treatment of patients with advanced renal cell carcinoma in combination with everolimus. In addition, the efficacy of lenvatinib is being evaluated in other cancers, including hepatocellular carcinoma and endometrial cancer. The purpose of this study was to elucidate the mechanism underlying the clinical activities of lenvatinib by using in vitro and in vivo angiogenesis models. First, we established an in vitro tube formation system, in which capillary-like structures formed on basement membrane extract in response to pro-angiogenic factors. Lenvatinib suppressed tube formation induced by bFGF alone and by bFGF plus VEGF. Furthermore, plasma levels of VEGF and FGF23, pharmacodynamic biomarkers of inhibition of the VEGFR and FGFR signaling pathways, respectively, were up-regulated after the administration of lenvatinib to mice. By contrast, the administration of another VEGFR inhibitor, sorafenib tosylate (sorafenib), up-regulated plasma levels of VEGF but not FGF23. Finally, lenvatinib suppressed bFGF-driven angiogenesis in Matrigel plug assays at low dosage (3 mg/kg), whereas sorafenib did so only at a higher dose (30 mg/kg). These results indicate that lenvatinib inhibits both VEGFR and FGFR in vitro and in vivo. This combined inhibition of both VEGFR and FGFR may lead significant clinical activities.
Authors and Affiliations
Ichikawa Kenji, Miyano Saori Watanabe, Adachi Yusuke, Matsuki Masahiro, Okamoto Kiyoshi, Matsui Junji
Keywords
Related Articles
- EP ID EP352858
- DOI 10.17352/2581-5407.000009
- Views 100
- Downloads 0
Is it Time for the Introduction of Colostomy Free Survival in Rectal Cancer Patients
The rectum is considered the straight part of the bowel although it’s not straight with at least three folds. Sometimes defined as the last 12 cm of the large bowel other consider it as the last 15 cm. Surgeons mark it s...
Financial Crisis and Health
The financial crisis has a dramatic impact on social life, since reduced or even non-existent incomes affect people’s well-being and push big parts of the population to poverty. The individuals’ financial status affects...
An Overview of Thyroid Cancer Genetics and Inheritance
Thyroid cancer (TC) is the most common endocrine malignancy and its incidence hasbeen increasing sharply since the mid-1990s [1]. TC is a general term that comprises two main groups of neoplasias, depending on the cell t...
Angiosarcoma of the Scalp and Face: A Hard to Treat Tumor
Cutaneous angiosarcoma is a rare and aggressive malignant tumor of vascular origin. Multimodality treatment including surgery, radiotherapy and chemotherapy should be used according to age and local spread. Prognosis is...
Primary Spindle Cell Rhabdomyosarcoma of Prostate: A Case Report with Review of Literature
Primary spindle cell rhabdomyosarcoma of the prostate is an uncommon variant of embryonal rhabdomyosarcoma seen in pediatric age group mostly during infancy and childhood. Rhabdomyosarcoma (RMS) arising from prostate pre...